CARSON CITY, Nev., March 04, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants ("Pre-funded Warrants") in lieu thereof) and warrants to purchase up to 10,500,000 shares of co ...

CARSON CITY, Nev., March 01, 2024 (GLOBE NEWSWIRE) -- Carson City, Nevada – March 1, 2024 – BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants ("Pre-Funded Warrants") in lieu thereof) in a best efforts public offering. All of the shares of common s ...

BioVie (NASDAQ:BIVI) stock is rocketing higher on Friday announed positive data from two clinical trials of NE3107.NE3107 is BioVie’s inhibitor of inflammatory activation of ERK and NFkB. These are both factors tied to Alzheimer’s and Parkinson’s diseases.The company’s Phase 3 of NE3107 in mild to moderate Alzheimer’s Disease patients suggests it may “realign physiological processes in patients consistent with decreased neurocognitive decline and diseases of aging.”As for its Phase 2a trial of Parkinson’s D ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

20 On August 1, 2021, the Company began sponsoring an employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the "401K Plan") pursuant to which, all employees meeting eligibility requirements are able to participate. Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Management's Discussion In neurodegenerative disease, the Company's drug candidate NE3107 inhibits activation of inflammatory actions extracellular singleregulated kinase ...

(Mark One) For the quarterly period ended: September 30, 2023 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Fair Value Measurements at June 30, 2023 You are cautioned not to place undue reliance on the forward-looking statements in this report, which speak only as of the date of this report. Ex ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. FOR THE FISCAL YEAR ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to _____________ Commission File Number: 001-39015 BIOVIE INC. (Exact name of registrant as specified in its charter) Nevada 46-2510769 (State or other jurisdictio ...

Previously, the Company was obligated to deliver contingent stock consideration to NeurMedix (or its successor) consisting of shares of the Company's common stock having an aggregate value of up to $3.0 billion, subject to the achievement of certain clinical, regulatory and commercial milestones related to the drug candidates to be acquired by the Company from NeurMedix, and subject to a cap limiting each issuance of shares if such issuance would result in the beneficial ownership of NeurMedix and its affil ...

On August 20, 2021, the Company awarded 58,759 restricted stock units ("RSUs") to the Company's President and CEO under the Company's 2019 Omnibus Incentive Equity Plan (the "2019 Omnibus Plan") as his salary for the period from April 27, 2021, the date of his appointment, through December 31, 2021. The number of RSUs awarded was based on a prorated annual base salary of $600,000 at a 10% discount to the grant date fair value of $7.74 per share of the Company's common stock. Each RSU awarded to the CEO enti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________to _____________ Commission File Number: 001-39015 BIOVIE INC. (Exact name of registrant as specified in its charter) Nevada 46-2510769 (State o ...